Next Article in Journal
The Role of Kirschner Wires in Foot and Ankle Surgery: A Comprehensive Review and Practical Appraisal of Applications, Benefits, and Challenges
Previous Article in Journal
Machine Learning Classification of Cognitive Status in Community-Dwelling Sarcopenic Women: A SHAP-Based Analysis of Physical Activity and Anthropometric Factors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 61
Issue 10
10.3390/medicina61101835
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effects of Thymoquinone on Cell Proliferation, Oxidative Damage, and Toll-like Signaling Pathway Genes in H1650 Lung Adenocarcinoma Cell Line

by
Selen Karaoğlanoğlu
1,* and
Gonca Gülbay
2
1
Department of Pulmonology, School of Medicine, Ordu University, 52200 Ordu, Türkiye
2
Department of Medical Biology, School of Medicine, Ordu University, 52200 Ordu, Türkiye
*
Author to whom correspondence should be addressed.
Medicina 2025, 61(10), 1835; https://doi.org/10.3390/medicina61101835
Submission received: 20 August 2025 / Revised: 3 October 2025 / Accepted: 12 October 2025 / Published: 14 October 2025
(This article belongs to the Section Pulmonology)
Browse Figures
Versions Notes

Abstract

Background and Objectives: Lung cancer is the leading cause of cancer-related mortality worldwide. In most cases, lung cancer is diagnosed at an advanced stage. For advanced-stage disease, treatment options are generally systemic and while novel treatment approaches offer hope, they may also lead to significant adverse effects. Therefore, alternative therapeutic strategies have been investigated for many years. Thymoquinone (TQ) is one such candidate. Previous studies have demonstrated its antioxidant, anti-inflammatory, antibacterial, and immunomodulatory properties. In our study, we aimed to evaluate the roles of TQ in the progression of H1650 lung adenocarcinoma cells. Materials and Methods: In this study, the antiproliferative effect of TQ on H1650 lung cancer cells was evaluated using MTT assay, its effect on oxidative damage was determined using 8-OHdG, and total antioxidant status (TAS), total oxidant status (TOS), and its effect on apoptosis were demonstrated using caspase-3 ELISA method. In addition, total RNA was extracted from both control and treatment groups, cDNA was synthesized, and mRNA expression changes of Toll-like receptor related genes (TLR) were analyzed using RT-PCR. Results: The decrease in the viability of H1650 lung cancer cells was observed in a time- and dose-dependent manner. The IC50 dose of TQ in the H1650 lung cancer cell line at 48 h was 26.59 µM. TQ treatment decreased the level of TOS and increased the level of TAS in H1650 lung cancer cells. Oxidative stress index decreased in the TQ-treated dose group in H1650 lung cancer cells. Elisa 8-OHdG and caspase-3 levels were not statistically significant. Compared to the control group, no statistically significant changes were observed in TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, and TLR9 gene expressions in the treatment group treated with 26.59 µM TQ for 48 h. Conclusions: TQ shows potential as an anticancer agent and may contribute to the development of therapeutic approaches for lung cancers.

1. Introduction

Lung cancer remains the deadliest cancer worldwide, accounting for 1.8 million deaths [1]. It is the most commonly diagnosed cancer in men globally and ranks second in women after breast cancer [2]. In cases of non-small cell lung cancer (NSCLC) diagnosed at an early stage, surgical intervention is the primary treatment option. However, in advanced stages, treatment typically consists of systemic therapies such as chemotherapeutic agents and targeted therapies [3,4]. Most patients with lung cancer are diagnosed at an advanced stage, as the disease often does not cause noticeable symptoms in its early stages. Symptoms such as cough, chest pain, and fatigue generally appear after the tumor has grown and metastasized. Due to genetic instability, high tumor mutational burden, and immune evasion mechanisms, lung cancers tend to progress rapidly, grow aggressively, and metastasize early [5,6].
Lung cancer is a disease that develops not only due to genetic mutations but also due to the effects of chronic inflammation. Excessive or abnormal activation of TLRs can cause effects such as disruption of the immune system’s balance, maintenance of chronic inflammation in the tumor microenvironment, release of pro-tumor cytokines, attraction of immunosuppressive cells to the tumor site, and suppression of the anti-tumor immune response [7,8]. For example, various studies have shown that TLR9 activation can enhance invasion and metastasis by increasing the expression of matrix metalloproteinases in tumor cells, while also supporting the angiogenesis process by increasing VEGF production. On the other hand, TLR4 activation has been shown to increase the release of proinflammatory cytokines by activating signaling pathways such as MAPK. This will clearly lead to the continuation of chronic inflammation and support tumor cell proliferation [9,10].
Therefore, intensive systemic therapy is often required in the treatment of lung cancer. While these therapies are certainly life-saving, they also carry a significant risk of adverse effects [11,12,13,14]. Numerous studies have long been conducted on alternative therapeutic approaches to support conventional medicine and reduce treatment-related side effects [15,16,17]. The emergence of targeted therapies, particularly tyrosine kinase inhibitors, has revolutionized treatment strategies for specific subgroups of patients with genetic mutations such as alterations in the epidermal growth factor receptor (EGFR) gene [18]. However, the development of resistance mechanisms and the lack of durable responses highlight the need for continued exploration of alternative treatment strategies. Plant-derived bioactive compounds like Thymoquinone (TQ), curcumin, and resveratrol have demonstrated antiproliferative, proapoptotic, and antioxidant effects in various lung cancer cell lines and animal models [19,20,21].
TQ is the primary bioactive compound derived from Nigella sativa seeds and has been shown to inhibit proliferation, migration, and invasion in the A549 human lung adenocarcinoma cell line [22]. TQ has attracted attention as a potential natural agent that can enhance the efficacy of existing cancer therapies while reducing their associated side effects. The combined administration of TQ with other anticancer drugs has demonstrated synergistic effects, contributing to improved treatment outcomes. In various cancer types, TQ has exhibited a wide range of biological activities, including inhibition of cell proliferation, induction of apoptosis, suppression of invasion, metastasis, enhancement of chemosensitivity, anti-angiogenic effects, and anti-inflammatory properties [23]. In one study, TQ showed greater cytotoxic and apoptotic effects in laryngeal cancer cells without KRAS mutations compared to those with the mutation [24]. NSCLCs frequently harbor KRAS driver mutations, and half of these are KRAS. KRAS mutant NSCLC, mutated in conjunction with STK11 and/or KEAP1, is particularly resistant to conventional, targeted, and immunotherapy. KRAS is a gene that regulates cell division and growth. Monoallelic variants in KRAS cause uncontrolled cell division, leading to cancer development. Studies have shown that cancer cells with KRAS mutations are often resistant to certain chemotherapies and targeted therapies [25]. Furthermore, during the COVID-19 pandemic, TQ was reported to exert protective effects in cancer patients by reducing SARS-CoV-2 entry into host cells and mitigating multi organ damage [26].
In this in vitro study, we used the H1650 cell line, a well-characterized model of lung adenocarcinoma. The H1650 cell line is an NSCLC model in which the EGFR-PI3K/AKT pathways are active due to EGFR exon 19 deletion and PTEN loss. These characteristics create tumor microenvironment conditions that may affect the expression levels of genes belonging to the TLR family (TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, TLR9). Therefore, the H1650 cell line was chosen in our study to evaluate TLR gene expression profiles [27,28]. Our aim was to investigate the effects of TQ on cell proliferation, oxidative DNA damage, apoptosis, and the expression of Toll-like receptor signaling pathway genes in H1650 lung adenocarcinoma cells. To our knowledge, this is the first study to investigate the anticancer effects of TQ on the H1650 lung cancer cell line. Understanding the potential of TQ in lung cancer treatment may contribute to the development of novel therapeutic strategies and serve as a basis for future clinical research.

2. Materials and Methods

2.1. Cell Culture

TQ was purchased from Sigma-Aldrich (St. Louis, MO, USA). H1650 cancer cells (the H1650 cell line was obtained from Dr. Şakir Akgün, Kafkas University, Kars, Türkiye) were grown in RPMI 1640 (Gibco Laboratories, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Ebsdorfergrund, Germany; Capricorn Scientific GmbH), 20 μg/mL streptomycin, 20 units/mL penicillin, 1 mM sodium pyruvate (Biological Industries, Beit-Haemek, Israel), and 0.1 mM amino acid solution (Biological Industries, Israel) and cultured at 37 °C in 5% CO2 in this study. We applied the active ingredient TQ to H1650 cells at different concentrations: 6.25 µM, 12.50 µM, 25.00 µM, 50.00 µM, 100.00 µM, and 200.00 µM.

2.2. Cell Viability Assay

The antiproliferative effects of TQ on H1650 lung cancer cells were determined using MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium] assay at a concentration of 2.104 cells per well in 96-well plates according to the kit’s instructions (Cell Proliferation Kit; GoldBio, St. Louis, MO, USA). After the dose intervals were completed, the MTT combination was applied in accordance with the dose and duration recommended by the manufacturer and measured spectrophotometrically. The protocols of the relevant kits were followed. Absorbance (570 nm) was measured using the Biotek Epoch 2 microplate reader and Gen5 software (Gen5 version 3.10).
Cell Viability (%) = [(Treatment group OD570 − Blank well OD570)/(Untreated group OD570 − Blank well OD570)] × 100%
The IC50 dosage was used as the dose group in the other molecular studies of this study.

2.2.1. Total Antioxidant Status and Total Oxidant Status Assay

The Rel Assay TAS and TOS kit (Rel Assay Kit Diagnostics, Gaziantep, Turkey) was used to determine the effects of TQ on the total antioxidant and oxidant status in H1650 lung cancer cells. The study was conducted in accordance with the manufacturer’s instructions. TAS and TOS values were measured using the Biotek Epoch 2 (Santa Clara, CA, USA) microplate reader and Gen5 software (Gen5 version 3.10). TAS and TOS value was calculated according to the following formula.
TOS = [(ΔAbsSample)/(ΔAbsStandard) × Concantration of standard]
TAS = [(ΔAbs H2O) − (ΔAbs Sample)/(ΔAbs H2O) − (ΔAbs Standard)]

2.2.2. Oxidative Stress Index Assay

The Oxidative Stress Index (OSI) serves as a measure of oxidative stress levels and is a unitless parameter calculated by taking the ratio of TOS to TAS [29]. To facilitate this calculation, TAS was initially converted from mmol Trolox equivalents per liter to µmol Trolox equivalents per liter.
OSI = [(TOS, µmol H2O2 equivalents/L)/(TAS, µmol Trolox equivalents/L) × 100].

2.2.3. 8-Hydroxy-2′-Deoxyguanosine Assay

Human 8-Hydroxy-2 Deoxyguanosine (8-OHdG) biomarker, which indicates DNA damage caused by oxidative stress, was determined by ELISA method. 8-OHdG (Bioassay Technology Laboratory, BT Lab, Shanghai, China) determination was carried out by following the BT Lab (Shanghai, China) kit and protocols. The detection range was 50 to 800 ng/mLfor 8-OHdG.

2.2.4. Caspase-3 Assay

The concentration of protein caspase-3 in TQ H1650 lung cancer cells was evaluated using the ELISA Kit from BT Lab (Bioassay Technology Laboratory, BT Lab, Shanghai, China) according to the protocols provided by the manufacturer. The detection range was 0.75 to 12 ng/mL for Caspase-3.

2.2.5. Total RNA Isolation, cDNA Synthesis, and RT-PCR Analysis

Total RNA isolation from cells was carried out using trizol (Invitrogen, Life Technologies, Carlsbad, CA, USA) in accordance with the manufacturer’s instructions. The A.B.T. synthesis kit with RNase Inhibitor was used for cDNA synthesis (A.B.T, Laboratory Industries, Ankara, Türkiye). Real-time PCR (RT-PCR, Rotor-Gene Q, Hilden, Germany) was used to assess changes in mRNA expression of (Toll-like receptor genes, TLR) TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, and TLR9. Normalization was accomplished through the use of Beta-Actin (ACTB). The primer sequences used in this study were given in Table 1 [30]. RT-PCR was used to perform real-time PCR (Rotor Gene Q, Qiagen) tests using the SYBR Green qPCR Master Mix ABTTM 2X qPCR SYBR-Green Master Mix (Turkey) protocol.

2.3. Statistical Analysis

All statistical analyses were carried out using GraphPad Prism 9.4.1 software (GraphPad Software, San Diego, CA, USA). The real-time PCR quantification was performed via the 2−∆∆CT method, with further analysis using the Gene Globe RT-PCR Analysis RT2 Profile PCR Array Data Analysis platform (Qiagen). Values were reported as mean ± S.D. For the comparison of multiple groups, we used analysis of variance (one-way ANOVA) to assess statistical significance between the groups. Post-hoc comparisons were performed using Dunnett’s test, to compare each mean with a control mean. The normality of data distribution was assessed using the Shapiro–Wilk test to determine the suitability of parametric or non-parametric statistical tests. When comparing two groups, either an unpaired t-test or Mann–Whitney test was used, depending on the distribution of the data. A p-value of <0.05 was considered statistically significant (ns p > 0.05, * p ≤ 0.05).

3. Results

3.1. MTT Analysis

Upon treatment with TQ, the viability of H1650 cells was assessed using the MTT assay. A decrease in cell viability was observed in a time- and dose-dependent manner. The half-maximal inhibitory concentration (IC50) dose of TQ was determined as 26.59 µM at 48 h in the H1650 cell line (Figure 1).

3.2. Total Antioxidant Status (TAS), Total Oxidant Status (TOS), and Oxidative Stress Index (OSI) Analysis

To determine the effects of TQ on oxidative stress in H1650 lung cancer cells, TAS, TOS, and OSI values were calculated. TQ treatment decreased the total oxidant status level and increased the total antioxidant status level in H1650 lung cancer cells (TAS, control group: 254.2 ± 89.89, TQ-treated: 803.0 ± 8.98, p = 0.33; TOS, control group: mean 25.57 ± 1.432, TQ-treated: mean 12.91 ± 0.358, p = 0.33) (Figure 2a,b). Oxidative stress index decreased in the TQ-treated dose group in H1650 lung cancer cells (control group: mean 10.62 ± 3.191, TQ-treated: mean 1.60 ± 0.026, p = 0.33) (Figure 2c). The administration of TQ appears to suppress the generation of reactive oxygen species (ROS), thereby mitigating oxidative stress. Elevated ROS levels are recognized as key modulators in the activation of redox-sensitive signaling cascades, which contribute significantly to oncogenesis and tumor progression.

3.3. 8-Hydroxy-2′-Deoxyguanosine (8-OHdG) Analysis

8-OHdG level was investigated by ELISA method. Changes in protein concentration were determined by comparing TQ-treated H1650 lung cancer cells with the control group. According to the data, the mean 8-OHdG concentration in the H1650 control group was 0.94 ± 0.401 ng/mL, while it was 0.86 ± 0.069 ng/mL in TQ-treated cells. When the results were compared statistically, no significant difference was found (p > 0.99, Figure 3).

3.4. Caspase-3 Analysis

To determine whether TQ further induced caspase-3 activation in H1650 lung cancer cells, caspase-3 protein levels were examined using ELISA. Accordingly, the mean caspase-3 levels in cells were determined as 0.84 ± 0.137 for the control group and 0.81 ± 0.023 for TQ-treated H1650 cells. No significant difference was found when the results were statistically compared (p > 0.99, Figure 4).

3.5. Real Time-PCR Analysis

After total RNA was isolated from control and dose group cells, the cDNA synthesis was performed. The expression analysis of TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, and TLR9 was performed by RT-PCR according to the SYBR Green qPCR master mix protocol. As a result of RT-PCR, mRNA expression changes of genes involved in the apoptosis pathway were evaluated.
In the group treated with 26.59 µM TQ at the 48th hour, no significant changes were observed in the gene expressions of TLR1 (1.24-fold, p = 0.28), TLR2 (1.25-fold, p = 0.45), TLR3 (1.38-fold, p = 0.42), TLR4 (1.87-fold, p = 0.06), TLR6 (1.18-fold, p = 0.30), TLR7 (1.62-fold, p = 0.09), TLR8 (1.99-fold, p = 0.06), and TLR9 (1.27-fold, p = 0.33) when compared to the control group.

4. Discussion

Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with NSCLC accounting for approximately 85% of all cases. Despite advances in diagnosis and treatment, the prognosis for lung cancer patients remains poor, underscoring the urgent need for novel therapeutic strategies. In recent years, increasing attention has been directed toward naturally derived compounds with potential anticancer properties. TQ, the bioactive component of Nigella sativa, has shown promising effects in various cancer models due to its pro-apoptotic, antioxidant, and immunomodulatory activities. This is the first study to evaluate the effects of TQ on cell viability, oxidative stress parameters, apoptosis markers, and TLR gene expression in the H1650 NSCLC cell line, investigating its anticancer potential. Our findings contribute to the growing body of evidence supporting the therapeutic potential of TQ in lung cancer.
Karimian et al. [15] investigated the anticancer effects of TQ on the A549 lung cancer cell line and reported an IC50 value of 40 µM. Khan et al. [31] examined the anticancer effects of TQ at 24, 48, and 72 h across various small cell lung cancer cell lines. According to their findings, H446 cells were the most sensitive to TQ at different incubation times, while DM579 cells exhibited the greatest resistance, particularly after 24 h of exposure. The same study also demonstrated the tumor-suppressive effects of TQ in vivo. Similarly, Samarghandian et al. [32] evaluated the effects of TQ in a dose- (25, 50, and 100 µM) and time-dependent (24, 48, and 72 h) manner on A549 and MRC5 lung cancer cell lines. Their results showed that TQ significantly inhibited the viability of A549 cancer cells in both a dose- and time-dependent manner, reducing cell viability by more than 60%. However, this effect was not observed in the noncancerous MRC5 cell line. Gurbilek et al. [33] calculated the IC50 value of TQ at 113.49 µM after 24 h in an NSCLC cell line.
The antiproliferative effects of TQ have also been investigated in various cancer types other than lung cancer. Osorio-Perez et al., reported IC50 values of 82.59 µM and 55.83 µM for TQ in colon (HCT 15) and prostate (PC3) cancer cell lines, respectively [34]. Seçme et al. [35] demonstrated the antiproliferative effect of TQ in a breast cancer cell line (MCF-7) with an IC50 value of 7.867 µM. He et al. [36] investigated the effect of TQ on cell viability in gastric cancer cell lines HGC-27 and MKN-45 and showed that increasing TQ concentrations inhibited cell viability more effectively using CCK-8 (cell counting kit-8) assay. In our study, we determined the IC50 value of TQ in H1650 lung cancer cell line as 26.59 µM after 48 h.
Oxidative stress (OS), which occurs when ROS production exceeds the body’s antioxidant defense mechanisms, plays a complex and important role in cancer. High levels of ROS can cause oxidative damage, triggering gene mutations and activation of oncogenic signaling pathways that are hallmarks of cancer initiation and progression [37]. Oxidative stress not only directly contributes to DNA damage and tumor progression but also acts as a key driver of chronic inflammation, which further strengthens the tumor-promoting microenvironment. Chronic inflammation is a fundamental contributor to cancer development and progression by promoting tumor initiation and metastasis through the production of pro-inflammatory cytokines, reactive oxygen species, and growth factors. Inflammatory microenvironments can promote genetic mutations, inhibit apoptosis. and facilitate angiogenesis, all of which are critical in tumor formation [38].
The effects of TQ on inflammation and oxidative stress are well documented [39,40]. Shakeel et al. [41] showed that TQ significantly increased mitochondrial ROS production in H1299 and A549 lung cancer cell lines. Khan et al. [39] reported that the anti-inflammatory activity of TQ was mediated by inhibition of the inducible nitric oxide synthase (iNOS) pathway and reduction of cyclooxygenase-2 (COX-2) expression. In our study, treatment with TQ at a concentration of 26.59 µM IC50 resulted in an increase in TAS (dose group: 803.0, control group: 254.2) and a decrease in TOS (dose group: 12.91, control group: 25.57). However, although the decrease in OSI in the group treated with TQ (dose group: 1.60, control group: 10.62) was significant, it was not reflected in the statistical results. We believe that this situation may have been due to intra-group variations preventing the results from reaching the significance threshold.
The oxidative form of DNA damage induced by oxidative stress is 8-OHdG. Karimian et al. [15] reported an increase in 8-OHdG levels in TQ-treated A549 lung cancer cells compared to the control group. In contrast to this study, in our study we measured 8-OHdG levels, a marker of oxidative DNA damage, at 0.94 ng/mL and 0.86 ng/mL in the control dose groups, respectively. Although our results were not statistically significant, they may indicate that the H1650 cell line is more sensitive to the DNA-damaging effects of TQ. The culture duration used in this study was sufficient for the evaluation of many cytotoxic and oxidative stress parameters; however, longer culture protocols may be required to more clearly demonstrate DNA damage markers such as 8-OHdG. This should be taken into consideration in future research.
This natural compound activates apoptosis and has also been shown to activate tumor-suppressing genes in different cell lines. In two separate studies using human colon cancer (HCT116) and breast cancer cells (MCF7), it has been shown to induce apoptosis via the P53 mechanism [42,43].
Alam et al. [44] showed that TQ induced the pro-apoptotic protein, Bax, while inhibiting the anti-apoptotic protein Bcl-2 in H1299 and A549 NSCLC cells. In the same study, it was also emphasized that the combined use of TQ and Quercetin gave more effective results. Zhu et al. [45] reported that TQ inhibited pulmonary arterial remodeling through the P38MAPK/NF-κB signaling pathway and showed a partially therapeutic effect on induced pulmonary arterial hypertension in rats. In the study by Samarghandian and et al. [32], TQ dose dependently activated both caspase-3 and caspase-9 in lung cancer cells compared to control cells. Dera et al. [46] demonstrated the pro-apoptotic effect of TQ in combination therapy with indirubin-3-monoxime both in vivo and in vitro by annexin assay, along with a decrease in the Bcl-2/Bax ratio. Caspase-3 is the main executor of proteolytic degradation in cells exposed to cytotoxic drugs, radiotherapy, or immunotherapy.
In our study, we analyzed caspase-3 protein levels using the ELISA method to determine whether TQ further induced caspase-3 activation in H1650 lung cancer cells. Accordingly, we determined the mean serum caspase-3 levels as 0.84 ± 0.137 in the control group and 0.81 ± 0.023 in TQ-treated H1650 cells. The results revealed that there was no statistically significant difference between the groups.
In humans, TLRs are components of the innate immune system [30]. Altered expression of TLRs has been reported in several cancer types, including prostate [47], liver [48], gallbladder [49], and endometrial cancer [50]. In the study conducted by Pomerenke et al., increased TLR activation was observed in patients with COPD, leading to increased TNF-α secretion [51]. However, studies investigating the effect of TQ on TLR expression in lung cancer types are extremely limited. In our study, although we observed an increase in TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, and TLR9 expression levels in the H1650 lung cancer cell line following TQ treatment, the results were not statistically significant.
This study has certain limitations. Firstly, the experimental findings were obtained using only a single cell line. This may constitute a certain limitation in terms of the generalizability of the results. However, the cell line used is a well-characterized model in [relevant biological process/disease] research, and the data obtained provide important preliminary findings for the literature. In future studies, validating these results in different cell lines would be beneficial in further strengthening their biological validity.

5. Conclusions

This study contributes to the growing body of evidence demonstrating the anticancer potential of TQ in lung cancer. In our experimental model using the H1650 NSCLC cell line, TQ exhibited a notable cytotoxic effect with an IC50 value of 26.59 µM at 48 h. Furthermore, TQ was shown to modulate oxidative stress by increasing TAS and decreasing TOS and OSI. Although 8-OHdG levels, an indicator of oxidative DNA damage, did not significantly differ between the treatment and control groups, the trend was consistent with existing literature on TQ’s pro-oxidant effects in cancer cells. Caspase-3 activation, a hallmark of apoptosis, was evaluated but did not show a statistically significant increase, suggesting that TQ-induced apoptosis in H1650 cells may be mediated through caspase-independent or alternative pathways. While upregulation of TLR gene expression was observed, the results were not statistically significant, highlighting the need for further investigation into the immunomodulatory role of TQ. Taken together, our findings support the potential of TQ as an anticancer agent and warrant further studies to elucidate its molecular mechanisms in NSCLC and its interaction with inflammatory and apoptotic pathways.

Author Contributions

Conceptualization, S.K. and G.G.; methodology, S.K. and G.G.; software, G.G.; validation, G.G.; formal analysis, G.G.; investigation, S.K. and G.G.; resources, S.K. and G.G.; data curation, G.G.; writing—original draft preparation, S.K. and G.G.; writing—review and editing, S.K. and G.G.; visualization, S.K. and G.G.; supervision, S.K. and G.G.; project administration, S.K.; funding acquisition, S.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by Ordu University Scientific Research Projects Coordination Unit (Project number: A-2419) Ordu, Türkiye.

Institutional Review Board Statement

An application was submitted to the Non-Interventional Research Ethics Committee of Ordu University, and the committee issued a decision stating that ethical approval was not required for this in vitro study (Date: 18 July 2025, Decision No: 254).

Data Availability Statement

The data sets and analyses from the study can be obtained from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
NSCLCNon-small cell lung cancer
TQThymoquinone
TLRToll-like receptor
EGFREpidermal growth factor receptor
TASTotal antioxidant status
TOSTotal oxidant status
OSIOxidative stress index
8-OHdGHuman 8-Hydroxy-2 Deoxyguanosine
RT-PCRReal-time PCR
ROSReactive oxygen species
OSOxidative stress
iNOSInducible nitric oxide synthase
COX-2Cyclooxygenase-2

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
  2. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2024, 74, 229–263. [Google Scholar] [CrossRef]
  3. Remon, J.; Soria, J.C.; Peters, S.; ESMO Guidelines Committee. Early and Locally Advanced Non-Small-Cell Lung Cancer: An Update of the ESMO Clinical Practice Guidelines Focusing on Diagnosis, Staging, Systemic and Local Therapy. Ann. Oncol. 2021, 32, 1637–1642. [Google Scholar] [CrossRef]
  4. Daly, M.E.; Singh, N.; Ismaila, N.; the Management of Stage III NSCLC Guideline Expert Panel. Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. J. Clin. Oncol. 2024, 42, 3058–3060. [Google Scholar] [CrossRef]
  5. Li, C.; Wang, H.; Jiang, Y.; Fu, W.; Liu, X.; Zhong, R.; Cheng, B.; Zhu, F.; Xiang, Y.; He, J.; et al. Advances in Lung Cancer Screening and Early Detection. Cancer Biol. Med. 2022, 19, 591–608. [Google Scholar] [CrossRef] [PubMed]
  6. Tarawneh, T.S.; Mack, E.K.M.; Faoro, C.; Neubauer, A.; Middeke, M.; Kirschbaum, A.; Holland, A. Diagnostic and Therapeutic Delays in Lung Cancer during the COVID-19 Pandemic: A Single Center Experience at a German Cancer Center. BMC Pulm. Med. 2024, 24, 320. [Google Scholar] [CrossRef] [PubMed]
  7. Park, S.; Kim, G.; Choi, A.; Kim, S.; Yum, J.S.; Chun, E.; Shin, H. Comparative Network-Based Analysis of Toll-like Receptor Agonist, L-Pampo Signaling Pathways in Immune and Cancer Cells. Sci. Rep. 2024, 14, 17173. [Google Scholar] [CrossRef] [PubMed]
  8. Hoden, B.; DeRubeis, D.; Martinez-Moczygemba, M.; Ramos, K.S.; Zhang, D. Understanding the Role of Toll-like Receptors in Lung Cancer Immunity and Immunotherapy. Front. Immunol. 2022, 13, 1033483. [Google Scholar] [CrossRef]
  9. Belmont, L.; Rabbe, N.; Antoine, M.; Cathelin, D.; Guignabert, C.; Kurie, J.; Cadranel, J.; Wislez, M. Expression of TLR9 in Tumor-Infiltrating Mononuclear Cells Enhances Angiogenesis and Is Associated with a Worse Survival in Lung Cancer. Int. J. Cancer 2014, 134, 765–777. [Google Scholar] [CrossRef]
  10. Perros, F.; Lambrecht, B.N.; Hammad, H. TLR4 Signalling in Pulmonary Stromal Cells Is Critical for Inflammation and Immunity in the Airways. Respir. Res. 2011, 12, 125. [Google Scholar] [CrossRef]
  11. Green, H.E.; Nieva, J. Clinical Management of Immune-Related Adverse Events Following Immunotherapy Treatment in Patients with Non-Small Cell Lung Cancer. J. Investig. Med. 2021, 69, 1281–1286. [Google Scholar] [CrossRef] [PubMed]
  12. Hines, J.B.; Bowar, B.; Levine, E.; Esposito, A.; Garassino, M.C.; Bestvina, C.M. Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2023, 24, 9429. [Google Scholar] [CrossRef]
  13. Wang, Q.; Liu, A.H.; Fan, H.J.; He, A.B.; Cao, D.D.; Hu, W.; Xu, H.L. The Incidences of Adverse Events in Small-Cell Lung Cancer Patients after Radiotherapy and Immunotherapy Treatment: A Systematic Review and Meta-Analysis. Eur. Rev. Med. Pharmacol. Sci. 2022, 26, 3062–3073. [Google Scholar] [CrossRef]
  14. Zhao, Q.; Liu, C.; Liu, H.; Chen, J. Advances in Immune Neoadjuvant/Adjuvant Therapy-Related Adverse Events of Non-Small Cell Lung Cancer. Asia Pac. J. Clin. Oncol. 2022, 18, 171–176. [Google Scholar] [CrossRef] [PubMed]
  15. Karimian, A.; Majidinia, M.; Moliani, A.; Alemi, F.; Asemi, Z.; Yousefi, B.; Fazlollahpour Naghibi, A. The Modulatory Effects of Two Bioflavonoids, Quercetin and Thymoquinone on the Expression Levels of DNA Damage and Repair Genes in Human Breast, Lung and Prostate Cancer Cell Lines. Pathol. Res. Pract. 2022, 240, 154143. [Google Scholar] [CrossRef] [PubMed]
  16. Sukprasansap, M.; Chanvorachote, P. Evidence of Potential Plant-Derived Compounds with Anticancer Effects on Lung Cancer: Clinical and Molecular Pharmacology Approaches. Anticancer. Res. 2022, 42, 4247–4258. [Google Scholar] [CrossRef]
  17. Virchea, L.I.; Frum, A.; Georgescu, C.; Pecsenye, B.; Mathe, E.; Mironescu, M.; Craciunas, M.T.; Totan, M.; Tanasescu, C.; Gligor, F.G. An Overview of the Bioactivity of Spontaneous Medicinal Plants Suitable for the Improvement of Lung Cancer Therapies. Pharmaceutics 2025, 17, 336. [Google Scholar] [CrossRef]
  18. Jeon, H.; Wang, S.; Song, J.; Gill, H.; Cheng, H. Update 2025: Management of Non-Small-Cell Lung Cancer. Lung 2025, 203, 53. [Google Scholar] [CrossRef]
  19. Kunnumakkara, A.B.; Bordoloi, D.; Harsha, C.; Banik, K.; Gupta, S.C.; Aggarwal, B.B. Curcumin Mediates Anticancer Effects by Modulating Multiple Cell Signaling Pathways. Clin. Sci. 2017, 131, 1781–1799. [Google Scholar] [CrossRef]
  20. Molassiotis, A.; Fernandez-Ortega, P.; Pud, D.; Ozden, G.; Scott, J.A.; Panteli, V.; Margulies, A.; Browall, M.; Magri, M.; Selvekerova, S.; et al. Use of Complementary and Alternative Medicine in Cancer Patients: A European Survey. Ann. Oncol. 2005, 16, 655–663. [Google Scholar] [CrossRef]
  21. Shukla, Y.; Singh, R. Resveratrol and Cellular Mechanisms of Cancer Prevention. Ann. N. Y. Acad. Sci. 2011, 1215, 1–8. [Google Scholar] [CrossRef]
  22. Yang, J.; Kuang, X.R.; Lv, P.T.; Yan, X.X. Thymoquinone Inhibits Proliferation and Invasion of Human Nonsmall-Cell Lung Cancer Cells via ERK Pathway. Tumour Biol. 2015, 36, 259–269. [Google Scholar] [CrossRef]
  23. Zhao, Z.; Liu, L.; Li, S.; Hou, X.; Yang, J. Advances in Research on the Relationship between Thymoquinone and Pancreatic Cancer. Front. Oncol. 2022, 12, 1092020. [Google Scholar] [CrossRef]
  24. Yenigun, V.B.; Acar, H.; Kanimdan, E.; Yenigun, A.; Kocyigit, A.; Cora, T. KRAS Mutation Reduces Thymoquinone Anticancer Effects on Viability of Cells and Apoptosis. Anticancer. Agents Med. Chem. 2023, 23, 1747–1753. [Google Scholar] [CrossRef] [PubMed]
  25. Mukhopadhyay, S.; Huang, H.Y.; Lin, Z.; Ranieri, M.; Li, S.; Sahu, S.; Liu, Y.; Ban, Y.; Guidry, K.; Hu, H.; et al. Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy. Cancer Res. 2023, 83, 4095–4111. [Google Scholar] [CrossRef] [PubMed]
  26. Elgohary, S.; Elkhodiry, A.A.; Amin, N.S.; Stein, U.; El Tayebi, H.M. Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients? Cells 2021, 10, 302. [Google Scholar] [CrossRef]
  27. Sos, M.L.; Koker, M.; Weir, B.A.; Heynck, S.; Rabinovsky, R.; Zander, T.; Seeger, J.M.; Weiss, J.; Fischer, F.; Frommolt, P.; et al. PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. Cancer Res. 2009, 69, 3256–3261. [Google Scholar] [CrossRef]
  28. Sui, X.; Han, X.; Chen, P.; Wu, Q.; Feng, J.; Duan, T.; Chen, X.; Pan, T.; Yan, L.; Jin, T.; et al. Baicalin Induces Apoptosis and Suppresses the Cell Cycle Progression of Lung Cancer Cells Through Downregulating Akt/MTOR Signaling Pathway. Front. Mol. Biosci. 2021, 7, 602282. [Google Scholar] [CrossRef]
  29. Acar, A.; Cevik, M.U.; Evliyaoglu, O.; Uzar, E.; Tamam, Y.; Arikanoglu, A.; Yucel, Y.; Varol, S.; Onder, H.; Tasdemir, N. Evaluation of Serum Oxidant/Antioxidant Balance in Multiple Sclerosis. Acta Neurol. Belg. 2012, 112, 275–280. [Google Scholar] [CrossRef]
  30. Gulbay, G.; Secme, M.; Mutlu, D. Fusaric Acid Inhibits Cell Proliferation and Downregulates Expressions of Toll-like Receptors Pathway Genes in Ishikawa Endometrial Cancer Cells. Eur. Rev. Med. Pharmacol. Sci. 2023, 27, 7431–7436. [Google Scholar] [CrossRef]
  31. Khan, M.; Lam, S.K.; Yan, S.; Feng, Y.; Chen, C.; Ko, F.C.; Ho, J.C. The Anti-Neoplastic Impact of Thymoquinone from Nigella Sativa on Small Cell Lung Cancer: In Vitro and in Vivo Investigations. J. Cancer Res. Ther. 2024, 20, 1224–1231. [Google Scholar] [CrossRef]
  32. Samarghandian, S.; Azimi-Nezhad, M.; Farkhondeh, T. Thymoquinone-Induced Antitumor and Apoptosis in Human Lung Adenocarcinoma Cells. J. Cell Physiol. 2019, 234, 10421–10431. [Google Scholar] [CrossRef]
  33. Gurbilek, M.; Deniz, C.D.; Eroglu Gunes, C.; Kurar, E.; Reisli, I.; Kursunel, M.A.; Topcu, C.; Koc, M. Anticancer Activity of Thymoquinone in Non-Small Cell Lung Cancer and Possible Involvement of PPAR-Gamma Pathway. Int. J. Radiat. Biol. 2025, 101, 370–381. [Google Scholar] [CrossRef]
  34. Osorio-Perez, S.M.; Estrada-Meza, C.; Ruiz-Manriquez, L.M.; Arvizu-Espinosa, M.G.; Srivastava, A.; Sharma, A.; Paul, S. Thymoquinone Potentially Modulates the Expression of Key Onco- and Tumor Suppressor MiRNAs in Prostate and Colon Cancer Cell Lines: Insights from PC3 and HCT-15 Cells. Genes 2023, 14, 1730. [Google Scholar] [CrossRef]
  35. Seçme, M.; Aybek, S.D.; Gülbay, G.; Dodurga, Y. The Effect of Thymoquinone on Cell Proliferation, 8-Hydroxy-2′-Deoxyguanosine Level and Expression Changes of DNA Repair and Oxidative Stress-Related Genes in MCF-7 Breast Cancer Cells. Pamukkale Med. J. 2025, 18, 304–312. [Google Scholar] [CrossRef]
  36. He, P.; He, Y.; Ma, J.; Liu, Y.; Liu, C.; Baoping, Y.; Dong, W. Thymoquinone Induces Apoptosis and Protective Autophagy in Gastric Cancer Cells by Inhibiting the PI3K/Akt/MTOR Pathway. Phytother. Res. 2023, 37, 3467–3480. [Google Scholar] [CrossRef]
  37. Jelic, M.D.; Mandic, A.D.; Maricic, S.M.; Srdjenovic, B.U. Oxidative stress and its role in cancer. J. Cancer Res. Ther. 2021, 17, 22–28. [Google Scholar] [CrossRef] [PubMed]
  38. Lee, G.; Walser, T.C.; Dubinett, S.M. Chronic Inflammation, Chronic Obstructive Pulmonary Disease, and Lung Cancer. Curr. Opin. Pulm. Med. 2009, 15, 303–307. [Google Scholar] [CrossRef] [PubMed]
  39. Khan, M.A.; Younus, H. Thymoquinone Shows the Diverse Therapeutic Actions by Modulating Multiple Cell Signaling Pathways: Single Drug for Multiple Targets. Curr. Pharm. Biotechnol. 2018, 19, 934–945. [Google Scholar] [CrossRef] [PubMed]
  40. Kundu, J.; Chun, K.S.; Aruoma, O.I.; Kundu, J.K. Mechanistic Perspectives on Cancer Chemoprevention/Chemotherapeutic Effects of Thymoquinone. Mutat. Res. 2014, 768, 22–34. [Google Scholar] [CrossRef]
  41. Shakeel, I.; Haider, S.; Khan, S.; Ahmed, S.; Hussain, A.; Alajmi, M.F.; Chakrabarty, A.; Afzal, M.; Imtaiyaz Hassan, M. Thymoquinone, Artemisinin, and Thymol Attenuate Proliferation of Lung Cancer Cells as Sphingosine Kinase 1 Inhibitors. Biomed. Pharmacother. 2024, 177, 117123. [Google Scholar] [CrossRef]
  42. El-Far, A.H.; Godugu, K.; Noreldin, A.E.; Saddiq, A.A.; Almaghrabi, O.A.; Al Jaouni, S.K.; Mousa, S.A. Thymoquinone and Costunolide Induce Apoptosis of Both Proliferative and Doxorubicin-Induced-Senescent Colon and Breast Cancer Cells. Integr. Cancer Ther. 2021, 20, 15347354211035450. [Google Scholar] [CrossRef] [PubMed]
  43. Zhou, M.; Liu, X.; Li, Z.; Huang, Q.; Li, F.; Li, C.Y. Caspase-3 Regulates the Migration, Invasion and Metastasis of Colon Cancer Cells. Int. J. Cancer 2018, 143, 921–930. [Google Scholar] [CrossRef] [PubMed]
  44. Alam, S.; Mohammad, T.; Padder, R.A.; Hassan, M.I.; Husain, M. Thymoquinone and Quercetin Induce Enhanced Apoptosis in Non-Small Cell Lung Cancer in Combination through the Bax/Bcl2 Cascade. J. Cell Biochem. 2022, 123, 259–274. [Google Scholar] [CrossRef]
  45. Zhu, N.; Zhao, X.; Xiang, Y.; Ye, S.; Huang, J.; Hu, W.; Lv, L.; Zeng, C. Thymoquinone Attenuates Monocrotaline-Induced Pulmonary Artery Hypertension via Inhibiting Pulmonary Arterial Remodeling in Rats. Int. J. Cardiol. 2016, 221, 587–596. [Google Scholar] [CrossRef] [PubMed]
  46. Dera, A.A.; Rajagopalan, P.; Al Fayi, M.; Ahmed, I.; Chandramoorthy, H.C. Indirubin-3-Monoxime and Thymoquinone Exhibit Synergistic Efficacy as Therapeutic Combination in in-Vitro and in-Vivo Models of Lung Cancer. Arch. Pharm. Res. 2020, 43, 655–665. [Google Scholar] [CrossRef]
  47. Rivera-Cruz, C.M.; Figueiredo, M.L. Evaluation of Human Adipose-Derived Mesenchymal Stromal Cell Toll-like Receptor Priming and Effects on Interaction with Prostate Cancer Cells. Cytotherapy 2023, 25, 33–45. [Google Scholar] [CrossRef]
  48. Huang, Y.; Cai, B.; Xu, M.; Qiu, Z.; Tao, Y.; Zhang, Y.; Wang, J.; Xu, Y.; Zhou, Y.; Yang, J.; et al. Gene Silencing of Toll-like Receptor 2 Inhibits Proliferation of Human Liver Cancer Cells and Secretion of Inflammatory Cytokines. PLoS ONE 2012, 7, e38890. [Google Scholar] [CrossRef]
  49. Ouyang, B.; Pan, N.; Zhang, H.; Xing, C.; Ji, W. MiR-146b-5p Inhibits Tumorigenesis and Metastasis of Gallbladder Cancer by Targeting Toll-like Receptor 4 via the Nuclear Factor-kappaB Pathway. Oncol. Rep. 2021, 45, 15. [Google Scholar] [CrossRef]
  50. Gulbay, G.; Secme, M.; Ilhan, H. Exploring the Potential of Thymoquinone-Stabilized Selenium Nanoparticles: In HEC1B Endometrial Cancer Cells Revealing Enhanced Anticancer Efficacy. ACS Omega 2023, 8, 39822–39829. [Google Scholar] [CrossRef]
  51. Pomerenke, A.; Lea, S.R.; Herrick, S.; Lindsay, M.A.; Singh, D. Characterization of TLR-Induced Inflammatory Responses in COPD and Control Lung Tissue Explants. Int. J. Chron. Obstruct. Pulmon. Dis. 2016, 11, 2409–2417. [Google Scholar] [CrossRef] [PubMed]
Medicina 61 01835 g001
Figure 1. H1650 lung cells were treated with TQ at different concentrations and time intervals, and their viability was assessed by MTT assay, ns, non-significant p > 0.05; * p ≤ 0.05.
Figure 1. H1650 lung cells were treated with TQ at different concentrations and time intervals, and their viability was assessed by MTT assay, ns, non-significant p > 0.05; * p ≤ 0.05.
Medicina 61 01835 g001
Medicina 61 01835 g002
Figure 2. Data are presented as mean ± SD. The Y-axis is plotted on a log10 scale. Modulation of the TAS, TOS, and OSI values in H1650 lung cancer cells by TQ. (a) TAS (control Group: 254.2 ± 89.89, TQ-treated: 803.0 ± 8.98), (b) TOS (control Group: 25.57 ± 1.432, TQ-treated: 12.91 ± 0.358), (c) OSI (control Group: 10.62 ± 3.191, TQ-treated: 1.60 ± 0.026).
Figure 2. Data are presented as mean ± SD. The Y-axis is plotted on a log10 scale. Modulation of the TAS, TOS, and OSI values in H1650 lung cancer cells by TQ. (a) TAS (control Group: 254.2 ± 89.89, TQ-treated: 803.0 ± 8.98), (b) TOS (control Group: 25.57 ± 1.432, TQ-treated: 12.91 ± 0.358), (c) OSI (control Group: 10.62 ± 3.191, TQ-treated: 1.60 ± 0.026).
Medicina 61 01835 g002
Medicina 61 01835 g003
Figure 3. 8-OHdG concentration levels of TQ-treated H1650 lung cancer cells and controls (ns, non-spesific; control group: 0.94 ± 0.401 ng/mL, TQ-treated: 0.86 ± 0.069 ng/mL, p > 0.99).
Figure 3. 8-OHdG concentration levels of TQ-treated H1650 lung cancer cells and controls (ns, non-spesific; control group: 0.94 ± 0.401 ng/mL, TQ-treated: 0.86 ± 0.069 ng/mL, p > 0.99).
Medicina 61 01835 g003
Medicina 61 01835 g004
Figure 4. Caspase-3 concentration levels of TQ-treated H1650 lung cancer cells and controls (ns, non-spesific; control group: 0.84 ± 0.137, TQ-treated 0.81 ± 0.023 p > 0.99).
Figure 4. Caspase-3 concentration levels of TQ-treated H1650 lung cancer cells and controls (ns, non-spesific; control group: 0.84 ± 0.137, TQ-treated 0.81 ± 0.023 p > 0.99).
Medicina 61 01835 g004
Table 1. Real-time PCR forward and reverse prime sequences [30].
Table 1. Real-time PCR forward and reverse prime sequences [30].
Gene NamesForwardReverseAmplicon Length
(bp)
(5′–3′)(5′–3′)
TLR1CAGCGATGTGTTCGGTTTTCCGGATGGGCAAAGCATGTGGACCA1151
TLR2TTATCCAGCACACGAATACACAGAGGCATCTGGTAGAGTCATCAA160
TLR3GGCTAGCAGTCATCCAACAGAAGCAGTCAGCAACTTCATGGC143
TLR4CCCTGAGGCATTTAGGCAGCTAGGTAGAGAGGTGGCTTAGGCT144
TLR6TTCTCCGACGGAAATGAATTTGCCAGCGGTAGGTCTTTTGGAAC75
TLR7CTTTGGACCTCAGCCACAACCACGCAACTGGAAGGCATCTTGTAG163
TLR8ACTCCAGCAGTTTCCTCGTCTCAAAGCCAGAGGGTAGGTGGGAA144
TLR9TGAGCCACAACTGCATCTCGCACAGTCGTGGTAGCTCCGTGAAT116
Beta–ActinCACCATTGGCAATGAGCGGTTCAGGTCTTTGCGGATGTCCACGT131
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Karaoğlanoğlu, S.; Gülbay, G. Effects of Thymoquinone on Cell Proliferation, Oxidative Damage, and Toll-like Signaling Pathway Genes in H1650 Lung Adenocarcinoma Cell Line. Medicina 2025, 61, 1835. https://doi.org/10.3390/medicina61101835

AMA Style

Karaoğlanoğlu S, Gülbay G. Effects of Thymoquinone on Cell Proliferation, Oxidative Damage, and Toll-like Signaling Pathway Genes in H1650 Lung Adenocarcinoma Cell Line. Medicina. 2025; 61(10):1835. https://doi.org/10.3390/medicina61101835

Chicago/Turabian Style

Karaoğlanoğlu, Selen, and Gonca Gülbay. 2025. "Effects of Thymoquinone on Cell Proliferation, Oxidative Damage, and Toll-like Signaling Pathway Genes in H1650 Lung Adenocarcinoma Cell Line" Medicina 61, no. 10: 1835. https://doi.org/10.3390/medicina61101835

APA Style

Karaoğlanoğlu, S., & Gülbay, G. (2025). Effects of Thymoquinone on Cell Proliferation, Oxidative Damage, and Toll-like Signaling Pathway Genes in H1650 Lung Adenocarcinoma Cell Line. Medicina, 61(10), 1835. https://doi.org/10.3390/medicina61101835

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop